Opinion

Video

Equitable Access to Molecular Testing and Treatment Prioritization

Author(s):

Ryan Haumschild, PharmD, MS, MBA, CPEL,Elizabeth Castronovo, NP

Panelists discuss how to overcome barriers to comprehensive molecular testing and how to prioritize treatment when ALK+ non–small cell lung cancer (NSCLC) coexists with other actionable biomarkers.

Molecular Testing and Biomarker Considerations

Key Themes:

  • Barriers to equitable access for comprehensive molecular testing
  • Strategies to overcome testing barriers
  • Treatment prioritization when ALK+ status coexists with other actionable biomarkers

Notable Insights:

  • Dr Dietrich identified barriers to comprehensive molecular testing including NGS
  • Grizzard offered suggestions for clinicians to overcome testing barriers

Dr Lovly addressed treatment prioritization in patients with both ALK+ status and other biomarkers (eg, PD-L1 >1%)

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Dr Carla Nester
AJMC interview with Ali Shan Hafeez and Dr Abdul Rafae Faisal | Background image credit: ipopba - stock.adobe.com
2 experts in this video
2 experts in this video
Julia Rotow, MD, Dana-Farber
Related Content
AJMC
August 2nd 2025

US Health Care Disparities in Immunology Biologics Access: A Systematic Review

Grace C. Wright, MD, PhD Ginette A. Okoye, MD Adam C. Ehrlich, MD, MPH D. J. Lorimier, PharmD, MS Shahnaz Khan, MPH Alisha Krumbach, PharmD Catherine Copley-Merriman, MS, MBA Kateryna Onishchenko, PhD Osayi Ovbiosa, PhD Manish Mittal, PhD
This article presents a systematic review of US health care disparities in biologics access across immunology (ie, rheumatology, dermatology, and gastroenterology) and a call to action.
managed care cast logo
August 2nd 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM
This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.
Heart health indicated with exercise, healthy eating, and medication | Image Credit: udra11 - stock.adobe.com
August 2nd 2025

Bridging the Gaps: New Strategies for Preventing Cardiovascular Disease

Laura Joszt, MA
During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discussed innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.
managed care cast logo
August 2nd 2025

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick
On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.
FIT test CRC - Paul Maguire - stock.adobe.com
August 2nd 2025

High Adenoma Detection Rates Linked to Lower CRC Rates, Worse Survival

Pearl Steinzor
In a large fecal immunochemical test-based screening program, high adenoma detection rates lowered interval colorectal cancer (CRC) incidence and mortality, but not CRC-specific survival.
Stethoscope with health icons next to a white piggy bank | Image credit: Kiattisak - stock.adobe.com
August 2nd 2025

Upfront HSCT More Cost-Effective for Patients With AML in Remission

Jared Kaltwasser
Proceeding with hematopoietic stem cell transplantation (HSCT) is more cost-effective than delaying the procedure in patients with intermediate-risk acute myeloid leukemia (AML).

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo